SynthesisFrontiers in immunology2026
Biomarker evidence for the pathophysiological mechanisms of insomnia: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insomnia is increasingly recognized as a systemic disorder involving persistent hyperarousal, neuroendocrine dysregulation, immune activation, and impaired stress adaptation. However, circulating biomarkers reflecting these interconnected biological processes have not been comprehensively synthesized. Methods: We conducted a systematic review and meta-analysis of observational studies comparing circulating biomarkers between adults with insomnia and healthy controls. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using random- or fixed-effects models as appropriate. Subgroup analyses, sensitivity analyses, and Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessments were performed to evaluate the robustness and certainty of the evidence. Results: Thirty-two studies involving 4578 individuals with insomnia and 28382 healthy controls were included. Cortisol levels were significantly elevated (SMD = 3.65, 95% CI: 2.35 to 4.95). Inflammatory biomarkers, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-1β (IL-1β), interleukin-2 (IL-2), and interferon-γ (IFN-γ), were significantly increased, whereas interleukin-4 (IL-4) and interleukin-10 (IL-10) showed no significant differences. Neuropeptide Y (NPY) was significantly reduced (SMD = -0.85, 95% CI: -1.27 to -0.43), while corticotropin-releasing hormone (CRH) and brain-derived neurotrophic factor (BDNF) showed no significant pooled differences. TNF-α, IL-1β, IL-6, CRP, and NPY showed generally consistent results in sensitivity analyses. Conclusions: Insomnia is associated with alterations in circulating biomarkers reflecting hypothalamic-pituitary-adrenal (HPA) axis activity, low-grade systemic inflammation, and potential reductions in stress-buffering capacity. This multidomain biomarker pattern provides insights into the biological basis of insomnia and highlights potential candidate biomarkers for future biological stratification. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261396725.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.